Apollo Global Management, Inc. (APO)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 20 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $159.95, which forecasts a 15.66% increase in the stock price over the next year. The lowest target is $125 and the highest is $194.

Price Target: $159.95 (+15.66%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$125	$159.95	$163	$194
Change	-9.61%	+15.66%	+17.87%	+40.28%

Analyst Ratings

The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	7	7	8	8	8	9
Buy	9	8	8	8	8	8
Hold	5	5	4	4	4	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	21	20	20	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Brown Wells Fargo	Wells Fargo	Buy Maintains $160 → $173	Buy	Maintains	$160 → $173	+25.10%	Jul 11, 2025
Christopher Allen Citigroup	Citigroup	Strong Buy Maintains $160 → $170	Strong Buy	Maintains	$160 → $170	+22.93%	Jul 10, 2025
Benjamin Budish Barclays	Barclays	Buy Maintains $156 → $168	Buy	Maintains	$156 → $168	+21.48%	Jul 10, 2025
Glenn Schorr Evercore ISI Group	Evercore ISI Group	Buy Maintains $150 → $155	Buy	Maintains	$150 → $155	+12.08%	Jul 10, 2025
Michael Brown Wells Fargo	Wells Fargo	Buy Maintains $158 → $160	Buy	Maintains	$158 → $160	+15.70%	May 23, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

18.73B

Decreased by -27.66%

from 25.89B

Revenue Next Year

22.24B

Increased by 18.75%

from 18.73B

EPS This Year

7.79

Increased by 6.32%

from 7.33

EPS Next Year

9.40

Increased by 20.65%

from 7.79

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.22B	5.81B	10.84B	31.94B	25.89B	18.73B	22.24B	25.64B
Revenue Growth	-21.62%	161.73%	86.55%	194.58%	-18.96%	-27.66%	18.75%	15.27%
EPS	0.44	7.31	-3.43	8.28	7.33	7.79	9.40	11.27
EPS Growth	-88.14%	1,562.03%	-	-	-11.51%	6.32%	20.65%	19.88%
Forward PE	-	-	-	-	-	17.75	14.71	12.27
No. Analysts	-	-	-	-	-	20	20	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	20.8B	31.3B	31.3B
Avg	18.7B	22.2B	25.6B
Low	17.5B	16.9B	18.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	-19.7%	67.2%	40.7%
Avg	-27.7%	18.8%	15.3%
Low	-32.4%	-9.6%	-15.4%

EPS Forecast

EPS	2025	2026	2027
High	8.37	10.27	12.19
Avg	7.79	9.40	11.27
Low	7.29	8.54	10.61

EPS Growth

EPS Growth	2025	2026	2027
High	14.2%	31.8%	29.7%
Avg	6.3%	20.6%	19.9%
Low	-0.5%	9.6%	12.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.